Paul Mischel, M.D. - Publications

Pathology University of California, San Diego, La Jolla, CA 
EGFR/PI3K/Akt/mTOR signaling network

141 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Harachi M, Masui K, Shimizu E, Murakami K, Onizuka H, Muragaki Y, Kawamata T, Nakayama H, Miyata M, Komori T, Cavenee WK, Mischel PS, Kurata A, Shibata N. DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma. Acta Neuropathologica Communications. 12: 40. PMID 38481314 DOI: 10.1186/s40478-024-01750-x  0.321
2023 Dehkordi SR, Wong IT, Ni J, Luebeck J, Zhu K, Prasad G, Krockenberger L, Xu G, Chowdhury B, Rajkumar U, Caplin A, Muliaditan D, Coruh C, Jin Q, Turner K, ... ... Mischel PS, et al. Breakage fusion bridge cycles drive high oncogene copy number, but not intratumoral genetic heterogeneity or rapid cancer genome change. Biorxiv : the Preprint Server For Biology. PMID 38168210 DOI: 10.1101/2023.12.12.571349  0.313
2023 Masui K, Mischel PS. Metabolic and epigenetic reprogramming in the pathogenesis of glioblastoma: Toward the establishment of "metabolism-based pathology". Pathology International. 73: 533-541. PMID 37755062 DOI: 10.1111/pin.13379  0.589
2023 Raviram R, Raman A, Preissl S, Ning J, Wu S, Koga T, Zhang K, Brennan CW, Zhu C, Luebeck J, Van Deynze K, Han JY, Hou X, Ye Z, Mischel AK, ... ... Mischel PS, et al. Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 120: e2210991120. PMID 37155843 DOI: 10.1073/pnas.2210991120  0.304
2023 West TJ, Bi J, Martínez-Peña F, Curtis EJ, Gazaniga NR, Mischel PS, Lairson LL. A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. Journal of the American Chemical Society. PMID 37017374 DOI: 10.1021/jacs.2c11715  0.344
2022 Pecorino LT, Verhaak RGW, Henssen A, Mischel PS. Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance. Biochemical Society Transactions. PMID 36355400 DOI: 10.1042/BST20221045  0.317
2022 Chen PB, Fiaux PC, Zhang K, Li B, Kubo N, Jiang S, Hu R, Rooholfada E, Wu S, Wang M, Wang W, McVicker G, Mischel PS, Ren B. Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation. Cell Reports. 41: 111630. PMID 36351387 DOI: 10.1016/j.celrep.2022.111630  0.312
2022 Noorani I, Mischel PS, Swanton C. Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. Nature Reviews. Clinical Oncology. PMID 36131011 DOI: 10.1038/s41571-022-00679-1  0.314
2022 Lange JT, Rose JC, Chen CY, Pichugin Y, Xie L, Tang J, Hung KL, Yost KE, Shi Q, Erb ML, Rajkumar U, Wu S, Taschner-Mandl S, Bernkopf M, Swanton C, ... ... Mischel PS, et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nature Genetics. PMID 36123406 DOI: 10.1038/s41588-022-01177-x  0.348
2022 Masui K, Cavenee WK, Mischel PS, Shibata N. The metabolomic landscape plays a critical role in glioma oncogenesis. Cancer Science. PMID 35271755 DOI: 10.1111/cas.15325  0.614
2021 Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, ... ... Mischel PS, et al. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports. 37: 109957. PMID 34731610 DOI: 10.1016/j.celrep.2021.109957  0.371
2021 Bakhoum MF, Francis JH, Agustinus A, Earlie EM, Di Bona M, Abramson DH, Duran M, Masilionis I, Molina E, Shoushtari AN, Goldbaum MH, Mischel PS, Bakhoum SF, Laughney AM. Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression. Nature Communications. 12: 5402. PMID 34518527 DOI: 10.1038/s41467-021-25529-z  0.35
2021 Harachi M, Masui K, Cavenee WK, Mischel PS, Shibata N. Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer. Metabolites. 11. PMID 33916219 DOI: 10.3390/metabo11040216  0.574
2021 Wu S, Bafna V, Mischel PS. Extrachromosomal DNA (ecDNA) in cancer pathogenesis. Current Opinion in Genetics & Development. 66: 78-82. PMID 33477016 DOI: 10.1016/j.gde.2021.01.001  0.33
2020 Harachi M, Masui K, Honda H, Muragaki Y, Kawamata T, Cavenee WK, Mischel PS, Shibata N. Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM. Molecular Cancer Research : McR. PMID 32366675 DOI: 10.1158/1541-7786.Mcr-20-0024  0.584
2020 Masui K, Harachi M, Cavenee WK, Mischel PS, Shibata N. mTOR complex 2 is an integrator of cancer metabolism and epigenetics. Cancer Letters. PMID 32145344 DOI: 10.1016/J.Canlet.2020.03.001  0.64
2020 Koga T, Chaim IA, Benitez JA, Markmiller S, Parisian AD, Hevner RF, Turner KM, Hessenauer FM, D'Antonio M, Nguyen ND, Saberi S, Ma J, Miki S, Boyer AD, Ravits J, ... ... Mischel PS, et al. Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. Nature Communications. 11: 550. PMID 31992716 DOI: 10.1038/S41467-020-14312-1  0.347
2020 Christiansen JH, Nguyen N, Verhaak R, Kim H, Bafna V, Mischel P, Hassig C. Extrachromosomal DNA (ecDNA) carrying amplified oncogenes as a biomarker for insensitivity to pembrolizumab treatment in gastric cancer patients. Journal of Clinical Oncology. 38: 3123-3123. DOI: 10.1200/Jco.2020.38.15_Suppl.3123  0.318
2019 Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nature Reviews. Cancer. PMID 31806884 DOI: 10.1038/S41568-019-0226-5  0.546
2019 Masui K, Harachi M, Ikegami S, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. The Journal of Biological Chemistry. PMID 31712311 DOI: 10.1074/Jbc.Ra119.011519  0.57
2019 Rajkumar U, Turner K, Luebeck J, Deshpande V, Chandraker M, Mischel P, Bafna V. EcSeg: Semantic Segmentation of Metaphase Images Containing Extrachromosomal DNA. Iscience. 21: 428-435. PMID 31706138 DOI: 10.1016/J.Isci.2019.10.035  0.394
2019 Wang X, Yang K, Wu Q, Kim LJY, Morton AR, Gimple RC, Prager BC, Shi Y, Zhou W, Bhargava S, Zhu Z, Jiang L, Tao W, Qiu Z, Zhao L, ... ... Mischel PS, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Science Translational Medicine. 11. PMID 31391321 DOI: 10.1126/Scitranslmed.Aau4972  0.384
2019 Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Mischel PS, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/J.Cmet.2019.06.014  0.36
2019 Gimple RC, Kidwell RL, Kim LJY, Sun T, Gromovsky AD, Wu Q, Wolf M, Lv D, Bhargava S, Jiang L, Prager BC, Wang X, Ye Q, Zhu Z, Zhang G, ... ... Mischel PS, et al. Glioma Stem Cell Specific Super Enhancer Promotes Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling. Cancer Discovery. PMID 31201181 DOI: 10.1158/2159-8290.Cd-19-0061  0.342
2019 Chowdhry S, Zanca C, Rajkumar U, Koga T, Diao Y, Raviram R, Liu F, Turner K, Yang H, Brunk E, Bi J, Furnari F, Bafna V, Ren B, Mischel PS. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Nature. PMID 31019297 DOI: 10.1038/S41586-019-1150-2  0.327
2019 Lucki NC, Villa GR, Vergani N, Bollong MJ, Beyer BA, Lee JW, Anglin JL, Spangenberg SH, Chin EN, Sharma A, Johnson K, Sander PN, Gordon P, Skirboll SL, Wurdak H, ... ... Mischel PS, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30846550 DOI: 10.1073/Pnas.1816626116  0.382
2019 Masui K, Onizuka H, Cavenee WK, Mischel PS, Shibata N. Metabolic reprogramming in the pathogenesis of glioma: Update. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30609184 DOI: 10.1111/Neup.12535  0.619
2019 Yang K, Wang X, Wu Q, Kim L, Morton A, Gimple R, Prager B, Shi Y, Zhou W, Bhargava S, Zhu Z, Jiang L, Tao W, Qiu Z, Zhao L, ... ... Mischel P, et al. STEM-22. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS Neuro-Oncology. 21: vi238-vi238. DOI: 10.1093/Neuonc/Noz175.995  0.476
2019 Koga T, Chaim I, Markmiller S, Benitez J, Parisian A, Miki S, Hessenauer F, Turner K, Venneti S, Malicki D, Wechsler-Reya R, Mischel P, Chen C, Yeo G, Furnari F. TMOD-28. AUTHENTIC HUMAN GLIOMA MODELING USING GENETICALLY ENGINEERED INDUCED PLURIPOTENT STEM CELLS Neuro-Oncology. 21: vi268-vi269. DOI: 10.1093/Neuonc/Noz175.1127  0.42
2018 Harachi M, Masui K, Okamura Y, Tsukui R, Mischel PS, Shibata N. mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression. International Journal of Molecular Sciences. 19. PMID 30347859 DOI: 10.3390/Ijms19103267  0.611
2018 Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG. Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response. Cancers. 10. PMID 30044378 DOI: 10.3390/Cancers10080243  0.316
2018 Bi J, Wu S, Zhang W, Mischel PS. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context. Biochimica Et Biophysica Acta. PMID 29775654 DOI: 10.1016/j.bbcan.2018.05.002  0.395
2017 Liu F, Mischel PS, Cavenee WK. Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. Npj Precision Oncology. 1: 1. PMID 29872691 DOI: 10.1038/s41698-017-0005-2  0.376
2017 Masui K, Kato Y, Sawada T, Mischel PS, Shibata N. Molecular and Genetic Determinants of Glioma Cell Invasion. International Journal of Molecular Sciences. 18. PMID 29207533 DOI: 10.3390/Ijms18122609  0.566
2017 Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, ... ... Mischel PS, et al. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 32: 856-868.e5. PMID 29198914 DOI: 10.1016/J.Ccell.2017.10.016  0.365
2017 Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. PMID 29035366 DOI: 10.1038/Nm.4418  0.342
2017 Liu F, Mischel PS. Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma. Wiley Interdisciplinary Reviews. Systems Biology and Medicine. PMID 28892308 DOI: 10.1002/wsbm.1398  0.406
2017 Zanca C, Villa GR, Benitez JA, Thorne AH, Koga T, D'Antonio M, Ikegami S, Ma J, Boyer AD, Banisadr A, Jameson NM, Parisian AD, Eliseeva OV, Barnabe GF, Liu F, ... ... Mischel PS, et al. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. PMID 28724615 DOI: 10.1101/Gad.300079.117  0.328
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, ... ... Mischel PS, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/J.Molcel.2017.05.030  0.767
2017 Satoshi K, Hirayama A, Sakamoto N, Sumita K, Yoshino H, Warren M, Kawaguchi R, Ozawa T, Onishi N, Wolfe K, Okumura K, Ramkissoon A, Chow LML, Malhotra A, Terakawa J, ... ... Mischel P, et al. CBIO-12. GTP METABOLIC SWITCH LEADS TO NUCLEOLAR TRANSFORMATION AND MALIGNANT GROWTH OF GLIOBLASTOMA Neuro-Oncology. 19: vi35-vi35. DOI: 10.1093/Neuonc/Nox168.134  0.324
2017 Koga T, Benitez J, Markmiller S, D’Antonio M, Parisian A, Saberi S, Turner K, Hessenauer M, Thorne AH, Zanca C, Mischel P, Frazer K, Yeo G, Cavenee W, Furnari F. TMOD-42. CRISPR/Cas9-EDITED HUMAN NEURAL STEM CELLS GIVE RISE TO BRAIN TUMORS RESEMBLING GLIOBLASTOMAS Neuro-Oncology. 19: vi263-vi263. DOI: 10.1093/Neuonc/Nox168.1078  0.328
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Mischel PS, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/J.Ccell.2016.09.008  0.604
2016 Masui K, Shibata N, Cavenee WK, Mischel PS. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. PMID 27427440 DOI: 10.1002/Bies.201600026  0.647
2016 Agnihotri S, Golbourn B, Huang X, Remke M, Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, MacKenzie D, Rakopoulos P, Ramaswamy V, Taccone MS, Mischel PS, Fuller GN, et al. PINK1 is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. Cancer Research. PMID 27325644 DOI: 10.1158/0008-5472.Can-15-3079  0.343
2016 Masui K, Cavenee WK, Mischel PS. Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathology. PMID 27295313 DOI: 10.1007/S10014-016-0265-5  0.607
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Mischel PS, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/J.Ccell.2016.03.012  0.801
2016 Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handbook of Clinical Neurology. 134: 97-120. PMID 26948350 DOI: 10.1016/B978-0-12-802997-8.00006-2  0.532
2015 Chang E, Pohling C, Natarajan A, Witney TH, Kaur J, Xu L, Gowrishankar G, L D'Souza A, Murty S, Schick S, Chen L, Wu N, Khaw P, Mischel P, Abbasi T, et al. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models. Journal of Neuro-Oncology. PMID 26650066 DOI: 10.1007/S11060-015-1972-1  0.425
2015 Masui K, Cavenee WK, Mischel PS. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathology (Zurich, Switzerland). 25: 755-9. PMID 26526943 DOI: 10.1111/Bpa.12307  0.631
2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, et al. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. PMID 26177599 DOI: 10.1002/Cncr.29422  0.603
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/Pnas.1511759112  0.63
2015 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918  0.379
2015 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, ... Mischel PS, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. The Journal of Clinical Investigation. 125: 1591-602. PMID 25798620 DOI: 10.1172/Jci78239  0.806
2015 Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research. 75: 394-404. PMID 25432173 DOI: 10.1158/0008-5472.Can-14-2004  0.374
2015 Shin YS, Wei W, Gini B, Mischel P, Heath J. Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr09  0.752
2015 Mischel P. Abstract IA11: Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia11  0.564
2015 Chang E, Pohling C, Natarajan A, Witney T, Kaur J, Xu L, Gowrishankar G, de Souza A, Schick S, Chan L, Wu N, Khaw P, Mischel P, Abbasi T, Usmani S, et al. DDEL-04AshwaMAX AND WITHAFERIN A INHIBITS GLIOMAS IN CELLULAR AND MURINE ORTHOTOPIC MODELS Neuro-Oncology. 17: v73.4-v73. DOI: 10.1093/Neuonc/Nov212.04  0.421
2015 Tanaka K, Sasayama T, Irino Y, Nagashima H, Satoh N, Mischel P, Kohmura E. CBM-17INCREASING EXPRESSION OF GLUTAMINASE C (GAC) mRNA IN MALIGNANT GLIOMAS Neuro-Oncology. 17: v72.4-v72. DOI: 10.1093/Neuonc/Nov211.17  0.436
2014 Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology & Medicine. 11: 255-63. PMID 25610711 DOI: 10.7497/j.issn.2095-3941.2014.04.004  0.428
2014 Gini B, Mischel PS. Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discovery. 4: 876-8. PMID 25092745 DOI: 10.1158/2159-8290.Cd-14-0635  0.706
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem. 25: 364-73. PMID 24856037 DOI: 10.1016/J.Tem.2014.04.002  0.664
2014 Qin Y, Fu M, Takahashi M, Iwanami A, Kuga D, Rao RG, Sudhakar D, Huang T, Kiyohara M, Torres K, Dillard C, Inagaki A, Kasahara N, Goodglick L, Braun J, ... Mischel PS, et al. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. The Journal of Biological Chemistry. 289: 13974-85. PMID 24644285 DOI: 10.1074/Jbc.M113.543728  0.367
2014 Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. Bmc Cancer. 14: 152. PMID 24593279 DOI: 10.1186/1471-2407-14-152  0.413
2014 Masui K, Cavenee WK, Mischel PS. mTORC2 dictates Warburg effect and drug resistance. Cell Cycle (Georgetown, Tex.). 13: 1053-4. PMID 24583874 DOI: 10.4161/Cc.28377  0.683
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Mischel PS, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328  0.773
2014 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annual Review of Pathology. 9: 1-25. PMID 23937436 DOI: 10.1146/annurev-pathol-011110-130324  0.313
2014 Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Current Pharmaceutical Design. 20: 2619-26. PMID 23859617 DOI: 10.2174/13816128113199990486  0.487
2014 Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Masui K, Gini B, Yang H, Mischel PS, Kohmura E. NT-39 * GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES Neuro-Oncology. 16: v167-v167. DOI: 10.1093/Neuonc/Nou265.37  0.772
2014 Gini B, Bonetti B, Mischel P. Hypoxia Regulation of Sensitivity to the Mechanistic Target of Rapamycin Kinase Inhibition (Mtorki) in Glioblastoma Multiforme Annals of Oncology. 25: iv571. DOI: 10.1093/Annonc/Mdu359.28  0.737
2013 Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. Plos One. 8: e80397. PMID 24260384 DOI: 10.1371/Journal.Pone.0080397  0.326
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, ... ... Mischel PS, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/J.Cmet.2013.09.013  0.777
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Mischel PS, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527  0.801
2013 Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1820-4. PMID 23978446 DOI: 10.2967/Jnumed.112.118497  0.367
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Mischel PS, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013  0.765
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Mischel PS, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.Cd-12-0502  0.464
2013 Wei W, Shi Q, Remacle F, Qin L, Shackelford DB, Shin YS, Mischel PS, Levine RD, Heath JR. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: E1352-60. PMID 23530221 DOI: 10.1073/Pnas.1303060110  0.351
2013 Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. Plos Genetics. 9: e1003253. PMID 23459592 DOI: 10.1371/Journal.Pgen.1003253  0.389
2013 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis. 34: 725-38. PMID 23455378 DOI: 10.1093/Carcin/Bgt086  0.744
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, ... ... Mischel PS, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110  0.798
2013 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Mischel PS, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/Ng.2538  0.333
2013 Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 23: 143-58. PMID 23352126 DOI: 10.1016/J.Ccr.2012.12.008  0.412
2013 Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. International Journal of Radiation Oncology, Biology, Physics. 85: 1206-11. PMID 23182702 DOI: 10.1016/J.Ijrobp.2012.10.008  0.328
2013 Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. Ajnr. American Journal of Neuroradiology. 34: 533-40. PMID 22997168 DOI: 10.3174/Ajnr.A3253  0.316
2013 Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Mischel P, ... ... Mischel PS, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174  0.312
2012 Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, ... ... Mischel PS, et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proceedings of the National Academy of Sciences of the United States of America. 109: 14164-9. PMID 22891331 DOI: 10.1073/Pnas.1211962109  0.386
2012 Babic I, Mischel PS. Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. Cancer Discovery. 2: 676-8. PMID 22886662 DOI: 10.1158/2159-8290.CD-12-0309  0.308
2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. Neuro-Oncology. 14: 1050-61. PMID 22670012 DOI: 10.1093/Neuonc/Nos126  0.684
2012 Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Science Translational Medicine. 4: 139ra84. PMID 22539746 DOI: 10.1126/Scitranslmed.3003923  0.573
2012 Muto J, Imai T, Ogawa D, Nishimoto Y, Okada Y, Mabuchi Y, Kawase T, Iwanami A, Mischel PS, Saya H, Yoshida K, Matsuzaki Y, Okano H. RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of Notch and PI3 kinase/Akt signaling pathways. Plos One. 7: e33431. PMID 22428049 DOI: 10.1371/Journal.Pone.0033431  0.325
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6  0.327
2012 Tran LM, Chang CJ, Plaisier S, Wu S, Dang J, Mischel PS, Liao JC, Graeber TG, Wu H. Determining PTEN functional status by network component deduced transcription factor activities. Plos One. 7: e31053. PMID 22347425 DOI: 10.1371/Journal.Pone.0031053  0.346
2012 Qi Q, He K, Yoo MH, Chan CB, Liu X, Zhang Z, Olson JJ, Xiao G, Wang L, Mao H, Fu H, Tao H, Ramalingam SS, Sun SY, Mischel PS, et al. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. The Journal of Biological Chemistry. 287: 6113-27. PMID 22215664 DOI: 10.1074/Jbc.M111.293605  0.4
2012 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 38: 271-91. PMID 22098029 DOI: 10.1111/J.1365-2990.2011.01238.X  0.586
2012 Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Molecular Cancer Research : McR. 10: 156-66. PMID 22086906 DOI: 10.1158/1541-7786.Mcr-11-0411  0.394
2012 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Current Topics in Microbiology and Immunology. 355: 135-69. PMID 22015553 DOI: 10.1007/82_2011_178  0.405
2012 Gini B, Guo D, Nathanson D, Shackelford D, Zhu S, Yang H, Tanaka K, Babic I, Akhavan D, Bonetti B, Mortensen D, Xu S, Raymon H, Chopra R, Mischel P. Abstract 1923: The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas Cancer Research. 72: 1923-1923. DOI: 10.1158/1538-7445.Am2012-1923  0.767
2012 Donoghue J, Kerr L, Longano A, Mischel P, Johns T. Abstract 1220: ErbB4: A novel therapeutic target in glioblastoma multiforme Cancer Research. 72: 1220-1220. DOI: 10.1158/1538-7445.Am2012-1220  0.358
2011 Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Plos One. 6: e28973. PMID 22194965 DOI: 10.1371/Journal.Pone.0028973  0.381
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Mischel PS, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124  0.756
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, ... ... Mischel PS, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.Cd-11-0102  0.757
2011 Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Molecular Cancer Research : McR. 9: 1668-85. PMID 22013079 DOI: 10.1158/1541-7786.Mcr-10-0563  0.312
2011 Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 16062-7. PMID 21900605 DOI: 10.1073/Pnas.1106704108  0.694
2011 Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro-Oncology. 13: 622-34. PMID 21558073 DOI: 10.1093/Neuonc/Nor023  0.392
2011 Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, et al. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. The Journal of Experimental Medicine. 208: 689-702. PMID 21464220 DOI: 10.1084/Jem.20102099  0.334
2011 Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6-11. PMID 21208902 DOI: 10.1158/1078-0432.CCR-09-2268  0.402
2011 Youssef M, Reinitz F, Cloughesy T, Mischel P, Guo D. Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C169  0.528
2010 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics and Personalized Medicine. 3: 79-85. PMID 23226044 DOI: 10.2147/Pgpm.S7940  0.314
2010 Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, DeJesus J, Kamei K, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, ... ... Mischel PS, et al. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Research. 70: 6128-38. PMID 20631065 DOI: 10.1158/0008-5472.Can-10-0076  0.349
2010 Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology. 12: 882-9. PMID 20472883 DOI: 10.1093/neuonc/noq052  0.352
2010 Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, ... ... Mischel PS, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 107: 6459-64. PMID 20308550 DOI: 10.1073/Pnas.0911188107  0.369
2010 Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle (Georgetown, Tex.). 9: 211-2. PMID 20023392 DOI: 10.4161/Cc.9.2.10540  0.367
2010 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/J.1750-3639.2009.00356.X  0.326
2010 Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology. 96: 359-67. PMID 19655089 DOI: 10.1007/s11060-009-9983-4  0.316
2009 Mischel P. A case for a science-informed perspective on health care reform. The Journal of Clinical Investigation. 119: 2855. PMID 20069712 DOI: 10.1172/Jci41038  0.332
2009 Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, ... ... Mischel PS, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling. 2: ra82. PMID 20009104 DOI: 10.1126/Scisignal.2000446  0.455
2009 Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Current Biology : Cb. 19: 1788-98. PMID 19836242 DOI: 10.1016/J.Cub.2009.09.048  0.308
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Mischel PS, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347  0.401
2009 Iwanami A, Cloughesy TF, Mischel PS. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes & Development. 23: 1699-704. PMID 19651981 DOI: 10.1101/gad.1832909  0.352
2009 Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America. 106: 12932-7. PMID 19625624 DOI: 10.1073/Pnas.0906606106  0.449
2009 Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 500-12. PMID 19560740 DOI: 10.1016/J.Nurt.2009.04.008  0.404
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, ... Mischel PS, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  0.4
2009 Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Research. 69: 3173-9. PMID 19318569 DOI: 10.1158/0008-5472.Can-08-3390  0.304
2008 Brown PD, Krishnan S, Sarkaria J, Wu W, Mischel P, Yong WH, Arusell R, Jenkins RB, Buckner JC, Giannini C. A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2016. PMID 27948420 DOI: 10.1200/Jco.2008.26.15_Suppl.2016  0.346
2008 Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Mischel P, Yong WH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5603-9. PMID 18955445 DOI: 10.1200/Jco.2008.18.0612  0.369
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, ... ... Mischel PS, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008  0.391
2008 Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, ... ... Mischel PS, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research. 86: 48-60. PMID 17722061 DOI: 10.1002/Jnr.21471  0.333
2007 Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 378-81. PMID 17255257 DOI: 10.1158/1078-0432.CCR-06-1992  0.472
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Mischel P, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  0.309
2006 Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, ... ... Mischel PS, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences of the United States of America. 103: 17402-7. PMID 17090670 DOI: 10.1073/pnas.0608396103  0.425
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  0.303
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392  0.43
2006 Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66: 1258-60. PMID 16636248 DOI: 10.1212/01.Wnl.0000250628.10420.D8  0.371
2006 Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research. 66: 159-67. PMID 16397228 DOI: 10.1158/0008-5472.CAN-05-0077  0.339
2005 Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3063. PMID 27945588 DOI: 10.1200/Jco.2005.23.16_Suppl.3063  0.342
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Mischel PS, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  0.331
2005 Stillman BN, Mischel PS, Baum LG. New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. Brain Pathology (Zurich, Switzerland). 15: 124-32. PMID 15912884 DOI: 10.1111/J.1750-3639.2005.Tb00507.X  0.348
2005 Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. The Journal of Biological Chemistry. 280: 26953-64. PMID 15908427 DOI: 10.1074/jbc.M502614200  0.387
2005 Cloughesy T, Yung A, Vrendenberg J, Aldape K, Eberhard D, Prados M, Vandenberg S, Klencke B, Mischel P. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome Journal of Clinical Oncology. 23: 1507-1507. DOI: 10.1200/Jco.2005.23.16_Suppl.1507  0.309
2003 Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biology & Therapy. 2: 242-7. PMID 12878856  0.385
2003 Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research. 63: 2742-6. PMID 12782577  0.391
2003 Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathology (Zurich, Switzerland). 13: 52-61. PMID 12580545  0.422
Show low-probability matches.